Market closed

ADMA Biologics/$ADMA

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About ADMA Biologics

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

Ticker

$ADMA

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Ramsey, United States

Employees

624

Website

www.admabiologics.com

ADMA Biologics Metrics

BasicAdvanced

$3.9B

58.82 $0.28

0.76 -

Price and volume

Market cap

$3.9B

Beta

0.76

52-week high

$21.84

52-week low

$4.82

Average daily volume

2.5M

Financial strength

Current ratio

7.088

Quick ratio

3.048

Long term debt to equity

47.519

Total debt to equity

48.033

Interest coverage (TTM)

6.82%

Management effectiveness

Return on assets (TTM)

19.89%

Return on equity (TTM)

35.55%

Valuation

Price to earnings (TTM)

58.825

Price to revenue (TTM)

9.928

Price to book

16.81

Price to tangible book (TTM)

17.11

Price to free cash flow (TTM)

48.216

Growth

Revenue change (TTM)

63.39%

Earnings per share change (TTM)

-360.41%

3-year revenue growth (CAGR)

77.45%

3-year earnings per share growth (CAGR)

-23.69%

What the Analysts think about ADMA Biologics

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for ADMA Biologics stock.

ADMA Biologics Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

ADMA Biologics Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

ADMA Biologics News

AllArticlesVideos

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Accesswire·1 month ago

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into ADMA Biologics Inc For Securities Law Violations

Accesswire·1 month ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Accesswire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ADMA

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for ADMA Biologics stock?

ADMA Biologics (ADMA) has a market cap of $3.9B as of January 15, 2025.

What is the P/E ratio for ADMA Biologics stock?

The price to earnings (P/E) ratio for ADMA Biologics (ADMA) stock is 58.82 as of January 15, 2025.

Does ADMA Biologics stock pay dividends?

No, ADMA Biologics (ADMA) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next ADMA Biologics dividend payment date?

ADMA Biologics (ADMA) stock does not pay dividends to its shareholders.

What is the beta indicator for ADMA Biologics?

ADMA Biologics (ADMA) has a beta rating of 0.76. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.